Overview

Detailed Summary

Viyash Scientific Limited, formerly Sequent Scientific Limited, is engaged in the pharmaceutical business with a focus on animal health, formulations, and API. The company has shown solid financial performance in Q3 FY26, with revenues of ₹8,584 million and EBITDA growing by 64% YoY. It has achieved significant margin expansion, reflecting strong operational efficiencies and strategic cost optimization.
The merger with Sequent Scientific Limited has enabled Viyash to unlock synergies across various business units, enhancing R&D, manufacturing capabilities, and market reach. This transformative merger has laid a strong foundation for sustained profitability and business growth.
Viyash has successfully entered into strategic partnerships, including a noteworthy agreement with Boehringer Ingelheim for distributing companion animal products in India, underscoring its commitment to expanding its footprint in the animal health sector.
The company is focusing on expanding its R&D capabilities, emphasizing the development of complex generics, which positions it to capture significant opportunities in the growing generics market for companion animals.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 9,133 Cr
Volatility: High Risk
P/E Ratio: 120.2
Industry P/E: 31.8
PEG Ratio: 0.8
P/B Ratio: 10.8
52W High: 260.30
52W Low: 134.25

Sales CAGR

1Y: 13.26%
3Y: -6.72%
5Y: -4.75%
10Y: -8.81%

Profit CAGR

1Y: 208.95%
3Y: 2.19%
5Y: -5.84%
10Y: 4.77%

ROE

TTM: 15.22%
3Y: -6.05%
5Y: 0.03%
10Y: 6.48%

ROCE

TTM: 18.17%
3Y: -0.12%
5Y: 4.66%
10Y: 5.32%

Technicals

‌

Forecasts

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
CORONA		1479.20	9,540 Cr	60.55	14.46	0.47	26.53	33.34	17.54
STAR		962.95	9,223 Cr	17.35	3.35	0.40	14.42	14.96	8.14
VIYASH		209.05	9,133 Cr	120.24	10.79	0.00	15.22	18.17	8.65
JSLL		654.95	8,277 Cr	26.37	23.41	0.16	42.02	46.06	36.87
SHILPAMED		404.95	8,212 Cr	49.11	3.37	0.12	6.35	8.41	4.29
PGHL		4965.00	8,206 Cr	28.08	13.24	2.53	49.51	65.17	32.81
AKUMS		497.00	8,114 Cr	23.92	2.58	0.00	10.07	8.99	6.29
Median: 7 Co.	—	654.95	8,277 Cr	28.08	10.79	0.16	15.22	18.17	8.65

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	346	329	361	390	369	391	402	441	424	858
Expenses	331	307	329	348	330	356	355	389	368	683
Operating Profit	15	22	32	42	39	35	46	52	56	176
OPM %	4.37	6.76	8.93	10.75	10.61	8.83	11.51	11.82	13.13	20.46
Other Income	9.72	7.28	-0.71	2.68	0.19	5.53	1.32	2.62	0.45	-27
Interest	13	13	12	16	14	15	15	14	14	17
Depreciation	15	15	16	16	17	17	16	15	15	59
Profit Before Tax	-3.09	1.49	2.64	12	7.90	8.10	16	26	27	73
Tax %	-122.65	-616.78	51.89	24.50	19.75	20.00	36.36	31.15	27.84	33.60
Net Profit	-6.88	11	1.27	9.06	6.34	6.48	10	18	20	49
EPS in Rs	-0.19	0.19	-0.02	0.15	0.06	0.07	0.21	0.32	0.33	0.87

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	689	849	1,039	1,179	1,362	1,413	1,421	1,370	1,551	1,603
Expenses	641	765	914	1,009	1,150	1,303	1,409	1,308	1,390	1,431
Operating Profit	48	85	125	170	212	109	12	61	162	172
OPM %	7.02	9.96	12.02	14.44	15.57	7.74	0.84	4.48	10.43	10.73
Other Income	11	15	8.67	10	-0.46	11	-58	-6.43	9.71	9.66
Interest	28	33	33	36	24	16	36	48	61	59
Depreciation	40	41	42	51	51	52	56	62	66	65
Profit Before Tax	-14	24	59	94	137	53	-138	-55	44	58
Tax %	3.66	56.91	3.41	12.79	23.55	15.43	11.39	45.81	27.19	29.50
Net Profit	-14	10	57	82	104	45	-122	-30	32	41
EPS in Rs	-0.32	0.58	1.12	1.63	2.32	0.94	-2.79	-0.83	0.49	1.74
Dividend Payout %	0.00	1.16	10.05	0.00	12.99	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	48	49	49	49	50	50	50	50	50	50
Reserves	898	928	599	657	637	678	642	649	607	654
Borrowings	267	360	256	275	297	277	365	444	488	481
Other Liabilities	315	568	439	406	478	388	394	387	396	416
Total Liabilities	1,528	1,905	1,343	1,388	1,463	1,393	1,451	1,529	1,540	1,602
Fixed Assets	586	684	476	498	577	536	564	605	592	586
CWIP	24	33	18	23	13	31	12	55	16	16
Investments	428	428	239	180	171	83	38	0.05	3.51	0.07
Other Assets	491	760	610	687	701	744	837	868	929	1,000
Total Assets	1,528	1,905	1,343	1,388	1,463	1,393	1,451	1,529	1,540	1,602

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-0.05	-7.19	45	116	115	115	31	17	31	83
Cash from Investing Activity	-310	-116	7.17	-68	-72	9.65	-94	-65	-5.92	-25
Cash from Financing Activity	309	147	-57	-20	-43	-139	67	32	-1.44	-61
Net Cash Flow	-1.82	24	-4.55	28	0.31	-14	3.75	-16	23	-2.15

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	53.00%	53.00%	53.00%	52.88%	52.88%	52.87%	52.85%	52.70%	52.70%	52.69%	52.41%	61.48%
FIIs	5.92%	6.29%	6.05%	6.13%	6.17%	5.71%	6.46%	6.11%	6.06%	6.16%	5.91%	3.16%
DIIs	2.93%	2.93%	3.24%	7.24%	7.60%	8.07%	10.01%	12.03%	12.84%	13.01%	12.93%	7.36%
Public	38.15%	37.79%	37.71%	33.75%	33.34%	33.35%	30.68%	29.16%	28.40%	28.14%	28.74%	28.00%
Total Shareholders	1,91,875	1,87,474	1,84,521	1,72,853	1,66,593	1,63,693	1,54,603	1,62,574	1,58,152	1,47,320	1,44,085	1,35,389

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Investor Presentation

Q4 FY25

Available on Pro Plan